Renrong Wu

Dr. Renrong Wu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JHJing Huang
Jing Huang
FLFangkun Liu
Fangkun Liu
ZTZiwei Teng
Ziwei Teng
JCJindong Chen
Jindong Chen
JZJingping Zhao
Jingping Zhao
RWRenrong Wu
Renrong Wu
Jing Huang, Fangkun Liu, Ziwei Teng, Jindong Chen, Jingping Zhao, Xiaoping Wang, Renrong Wu; Care for the psychological status of frontline medical staff fight

1 March 2019 in Psychiatry Research
Verified
Journal Article
Closed access
YYYe Yang
Ye Yang
YLYi Liu
Yi Liu
GWGuodong Wang
Guodong Wang
GHGangrui Hei
Gangrui Hei
XWXiaoyi Wang
Xiaoyi Wang
JZJingping Zhao
Jingping Zhao

5 July 2021 in Neuroscience Bulletin
Verified
Journal Article
Open access
PDF file
QWQiongqiong Wu
Qiongqiong Wu
XWXiaoyi Wang
Xiaoyi Wang
YWYing Wang
Ying Wang
YLYu-Jun Long
Yu-Jun Long
JZJing-Ping Zhao
Jing-Ping Zhao
RWRenrong Wu
Renrong Wu
The causal mechanisms and treatment for the negative symptoms and cognitive dysfunction in schizophrenia are the main issues attracting the attention of psychiatrists over the last decade. The first part of this review summarizes the pathogenesis of schizophrenia, especially the negative symptoms and cognitive dysfunction from the perspectives of genetics and epigenetics. The second part describes the novel medications and several advanced physical therapies (e.g., transcranial magnetic stimulation and transcranial direct current stimulation) for the negative symptoms and cognitive dysfunction that will optimize the therapeutic strategy for patients with schizophrenia in future.

15 May 2022 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
JHJing Huang
Jing Huang
DKDongyu Kang
Dongyu Kang
FZFengyu Zhang
Fengyu Zhang
YYYe Yang
Ye Yang
CLChenchen Liu
Chenchen Liu
RWRenrong Wu
Renrong Wu
Antipsychotic-induced weight gain is associated with alterations to the composition of the gut microbiota. The purpose of this study was to determine the effect of probiotics plus dietary fiber on antipsychotic-induced weight gain. Two sequential, randomized clinical trials were conducted. In Study 1, 90 drug-naïve, first-episode schizophrenia patients were randomized to receive either olanzapine plus probiotics or olanzapine monotherapy for 12 weeks. In Study 2, 60 drug-naïve, first-episode schizophrenia patients were randomly assigned to receive either olanzapine plus probiotics and dietary fiber or olanzapine monotherapy for 12 weeks. In Study 1, no significant differences in weight gain were observed between the two groups. The insulin resistance index (IRI) was lower in the olanzapine plus probiotics group compared with the olanzapine monotherapy group at week 12 (estimated mean difference, −0.65, [95% confidence interval (CI), −1.10 to −0.20]; p = .005). In Study 2, weight gain was lower in the probiotics plus dietary fiber group than in the olanzapine monotherapy group at week 12 (estimated mean difference −3.45 kg, [95% CI, −5.91 to −1.00]; p = .007). At week 12, IRI increased significantly in the olanzapine monotherapy group (mean, 1.74; standard deviation (SD) = 1.11, p < .001), but not in the olanzapine plus probiotics and dietary fiber group (mean 0.47, SD = 2.16, p = .35) with an estimated mean difference of −0.95 between the two groups [95% CI, −1.77 to −0.14]; p = .022). These results provide support for the efficacy and safety of probiotics plus dietary fiber in attenuating antipsychotic-induced weight gain in drug-naïve, first-episode schizophrenia patients.

5 July 2022 in Journal of Psychiatric Research
Verified
Journal Article
Open access
MGMenghui Gao
Menghui Gao
ZTZiwei Teng
Ziwei Teng
ZWZirou Wei
Zirou Wei
KJKun Jin
Kun Jin
JXJingmei Xiao
Jingmei Xiao
JHJing Huang
Jing Huang
Internet addiction (IA) among teenagers has been reported frequently in China, although research has seldom focused on vocational high school students. This study investigated the prevalence and risk factors among this special adolescent population. Moreover, we illustrate the complex relationship between obsessive-compulsive (OC) symptoms, insomnia, psychological states, and IA. A cross-sectional design was applied to collect information from three different vocational high schools in Hunan Province, China. Socio-demographic characteristics, OC symptoms, insomnia, depression, anxiety, and stress symptoms were compared between the IA and non-IA groups. Then, a structural equation model (SEM) was established to test our hypothesis regarding different paths from OC symptoms to IA. IA prevalence was 13.4% among 7990 vocational high school students. Individuals with IA were more likely to be male and students with more severe depression, stress, anxiety, and insomnia symptoms (all p < 0.001). SEM verified that OC symptoms were related to IA both directly and indirectly, where the latter relationship was mediated through insomnia or mental disorders. This study cannot confirm the causal relationships among the variables and should be generalized cautiously to other groups. More attention should be paid to Chinese vocational high school students, especially those with more severe OC symptoms, poor mental health, and insomnia. We should consider OC symptoms, insomnia, psychological suffering, and IA together when addressing related problems.

11 October 2023 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
TSTiannan Shao
Tiannan Shao
JHJing Huang
Jing Huang
YZYuxin Zhao
Yuxin Zhao
WWWeiyan Wang
Weiyan Wang
XTXiaohan Tian
Xiaohan Tian
RWRenrong Wu
Renrong Wu
Cognitive impairment is a core feature of schizophrenia, which is aggravated by antipsychotics-induced metabolic disturbance and lacks effective pharmacologic treatments in clinical practice. Our previous study demonstrated the efficiency of metformin in alleviating metabolic disturbance following antipsychotic administration. Here we report that metformin could ameliorate cognitive impairment and improve functional connectivity (FC) in prefrontal regions. This is an open-labeled, evaluator-blinded study. Clinically stable patients with schizophrenia were randomly assigned to receive antipsychotics plus metformin (N = 48) or antipsychotics alone (N = 24) for 24 weeks. The improvement in cognition was assessed by the MATRICS Consensus Cognitive Battery (MCCB). Its association with metabolic measurements, and voxel-wise whole-brain FC with dorsolateral prefrontal cortex (DLPFC) subregions as seeds were evaluated. When compared to the antipsychotics alone group, the addition of metformin resulted in significantly greater improvements in the MCCB composite score, speed of processing, working memory, verbal learning, and visual learning. A significant time × group interaction effect of increased FC between DLPFC and the anterior cingulate cortex (ACC)/middle cingulate cortex (MCC), and between DLPFC subregions were observed after metformin treatment, which was positively correlated with MCCB cognitive performance. Furthermore, the FC between left DLPFC A9/46d to right ACC/MCC significantly mediated metformin-induced speed of processing improvement; the FC between left A46 to right ACC significantly mediated metformin-induced verbal learning improvement. Collectively, these findings demonstrate that metformin can improve cognitive impairments in schizophrenia patients and is partly related to the FC changes in the DLPFC. Trial Registration: The trial was registered with ClinicalTrials.gov (NCT03271866). The full trial protocol is provided in Supplementary Material.